Loading
Life sciences · Journal article
Quality in Sport · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction and Purpose The increasing contribution of metabolic dysfunction-associated steatotic liver disease (MASLD) to hepatocellular carcinoma (HCC) has highlighted important limitations of conventional ultrasound-based surveillance. Obesity, hepatic steatosis, and heterogeneous liver parenchyma may impair visualization and reduce sensitivity for early-stage tumors. This review summarizes current evidence on HCC risk stratification, surveillance, diagnosis, and treatment, with particular emphasis on risk-adapted strategies in patients with MASLD. Materials and Methods Peer-reviewed literature was reviewed, with emphasis on studies addressing ultrasound-based surveillance, abbreviated magnetic resonance imaging (AMRI), elastography, biomarker-based risk models, liquid biopsy, radiomics, artificial intelligence, and recent advances in locoregional and systemic treatment. Results Ultrasound with or without alpha-fetoprotein remains the standard surveillance strategy for patients at increased risk of HCC, although its effectiveness is reduced when visualization is inadequate. In selected patients, alternative imaging approaches, including AMRI, may improve surveillance performance. Elastography, clinical risk models, and biomarker panels such as GALAD may support risk stratification, whereas liquid biopsy, radiomics, and artificial intelligence remain investigational. Advances in locoregional therapy, immunotherapy, and targeted therapy have also expanded treatment options across different stages of HCC. Conclusion The key challenge is to identify patients in whom ultrasound-based surveillance is insufficient rather than to replace ultrasonography universally. A risk-adapted strategy integrating individual HCC risk, ultrasound quality, and selected complementary tools may be particularly relevant in MASLD. Further prospective studies are needed to determine whether such approaches improve early detection and clinical outcomes.